Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 7/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680467 | 0.92 | LMNA (0.34) | EPHX1LMNAMEN1ALDH1A1CYP3A4 | |
| SCHEMBL5682484 | 0.83 | JAK2 (0.33) | EPHX1LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5678852 | 0.83 | LMNA (0.35) | LMNAMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL697497 | 0.77 | — | — | |
| SCHEMBL5334141 | 0.77 | LMNA (0.42) | LMNAMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL9035773 | 0.76 | SMN1; SMN2 (0.38) | EPHX1NAAASMN1; SMN2CHRM2CHRM4 | |
| SCHEMBL13316352 | 0.75 | LMNA (0.36) | LMNAMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL5334144 | 0.75 | LMNA (0.36) | LMNAMEN1ALDH1A1CYP3A4MAPT | |
| SCHEMBL5680245 | 0.74 | ALDH1A1 (0.34) | LMNAALDH1A1 | |
| SCHEMBL2377383 | 0.73 | LMNA (0.35) | LMNAMEN1ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1184396-B1 | (Meth)acrylate ester-based resin composition | NIPPON CATALYTIC CHEM IND (JP) | 2006-02-01 | — | — | EP | disclosed |
| US-6686413-B2 | AQUEOUS DISPERSON OF A POLYMER CONTAINING UNITS OF A CYCLOHEXYLALKYL ESTER OF (METH)ACRYLIC ACID | NIPPON SHOKUBAI CO., LTD. (JP) | 2004-02-03 | — | — | US | disclosed |
| US-6489396-B2 | A CYCLOHEXYL CONTAINING (METH)ACRYLIC ESTER-BASED POLYMER CROSSLINKED WITH A DI-FUNCTIONAL CROSSLINKING AGENT; LOW VISCOSITY RESIN FOR LOW VOLATILE ORGANIC COMPOUND (VOC)-PAINTS | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020091197-A1 | (Meth)acrylate ester-based resin composition | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-07-11 | — | — | US | disclosed |
| EP-1205498-A1 | (Meth)acrylate ester-based resin composition | Nippon Shokubai Co., Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-20020045702-A1 | (Meth)acrylate ester-based resin composition | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-04-18 | — | — | US | disclosed |
| EP-1184396-A1 | (Meth)acrylate ester-based resin composition | Nippon Shokubai Co., Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045702-A1 | (Meth)acrylate ester-based resin composition | MNAT1, MAT1A, COPE | EPHX1 376/4885NAAA 252/4885LMNA 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.